Vuity

The U.S. Food and Drug Administration (FDA) approved the first prescription eyedrops to treat presbyopia, an age-related vision disorder characterized by blurred close-range vision. VUITY eyedrops gained FDA approval in October 2021 after showing in clinical trials that they could provide clear, up-close vision support for several hours with minimal significant side effects.
Presbyopia mostly affects people older than 40, and it usually requires them to wear reading glasses or contact lenses when looking at small text or working on a computer.

Notes: 

• VUITY is available to the public by prescription. It is the only presbyopia drug of its kind, but nine similar eye drop products are in clinical development.
• So far, a prescription for VUITY is not covered by any major health insurer, by Medicare of by any vision insurance plan, because the drops are not considered “medically necessary.”
  
• The drops treat mild to intermediate presbyopia, but because they work for less than half a day, they can’t serve as a permanent replacement for reading glasses. They will reduce the amount of time you need to wear the glasses you use for reading.
• VUITY does not treat other eye conditions such as astigmatism, nearsightedness and farsightedness. People with existing eye defects will need to hang onto their prescribed eyewear for corrections – and may not benefit much from VUITY.
• A 30-day supply of VUITY goes for about $80, barring any store discounts. As with many new prescription medications, VUITY’s cost should decline over time but not in the immediate future.
• VUITY is not recommended for use at night or in low-light environments. According to the manufacturer, it’s dangerous to drive or operate heavy machinery at night while using VUITY.
• Other ocular and non-ocular side effects have been reported. It's very important that you discuss these potential side effects with your eye doctor before using Vuity. 
  

​

Schedule Appointment